07/31/2026 | Press release | Distributed by Public on 07/31/2026 14:35
|
Page
|
|
|
||||||
|
|
Consolidated Statement of Comprehensive Income
|
|||||||
|
|
Consolidated Statement of Changes in Equity
|
|||||||
|
|
Consolidated Balance Sheet
|
|||||||
|
|
Consolidated Cash Flow Statement
|
|||||||
|
|
Notes to the Financial Statements
|
|||||||
|
|
Note
|
|
£
|
|
£
|
||||||||||||
|
Turnover
|
4 |
|
|
|
68,565,945 | ||||||||||||
|
Cost of sales
|
|
|
|
|
(35,449,720) | ||||||||||||
|
Gross profit
|
|
|
|
|
33,116,225 | ||||||||||||
|
Distribution costs
|
|
|
|
|
(2,782,028) | ||||||||||||
|
Administrative expenses
|
|
|
|
|
(33,270,765) | ||||||||||||
|
Other operating income
|
5 |
|
|
|
2,111,440 | ||||||||||||
|
Operating loss
|
5 |
|
|
|
(825,128) | ||||||||||||
|
Loss on ordinary activities before interest
|
|
|
|
|
(825,128) | ||||||||||||
|
Profit on sale of fixed assets
|
7 | 2,123,156 | |||||||||||||||
|
Interest receivable and similar income
|
8 |
|
670,164 |
|
|
||||||||||||
|
Less: Interest payable
|
9 |
|
(41,700) |
|
|
||||||||||||
|
|
|
|
|
|
2,751,620 | ||||||||||||
|
Profit before tax
|
10 |
|
|
1,926,492 | |||||||||||||
|
Tax on profit
|
11 |
|
|
|
(249,810) | ||||||||||||
|
Profit for the financial year
|
|
|
|
|
1,676,682 | ||||||||||||
|
Other comprehensive income for the year
|
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|||||||||||||
|
Exchange losses on conversion of opening balances
|
|
|
|
|
(360,793) | ||||||||||||
|
Total comprehensive income for the year
|
|
|
|
|
1,315,889 | ||||||||||||
|
|
Share Capital
|
|
Capital
Redemption
Reserve
|
|
Profit and Loss Account
|
|
Total
|
||||||||||||||||
|
|
£
|
|
£
|
|
£
|
|
£
|
||||||||||||||||
|
Balance as at 1st October 2024
|
948
|
|
52
|
|
101,800,502 |
|
101,801,502 | ||||||||||||||||
|
Profit for the year
|
- |
|
- |
|
1,676,682 |
|
1,676,682 | ||||||||||||||||
|
Other comprehensive loss
|
- |
|
- |
|
(360,793) |
|
(360,793) | ||||||||||||||||
|
Total comprehensive income
|
- |
|
- |
|
1,315,889 |
|
1,315,889 | ||||||||||||||||
|
Dividends paid
|
- |
|
- |
|
(450,000) |
|
(450,000) | ||||||||||||||||
|
Balance as at 30th September 2025
|
948
|
|
52
|
|
102,666,391 |
|
102,667,391 | ||||||||||||||||
|
|
Note
|
|
£
|
|
£
|
||||||||||||
|
Fixed assets
|
|
|
|
|
|
||||||||||||
|
Intangible assets
|
13 |
|
|
|
- | ||||||||||||
|
Tangible assets
|
14 |
|
|
|
53,709,695 | ||||||||||||
|
Investments
|
15 |
|
|
|
- | ||||||||||||
| 53,709,695 | |||||||||||||||||
|
Current assets
|
|
|
|||||||||||||||
|
Stock
|
16 |
|
17,778,610 |
|
|
||||||||||||
|
Debtors
|
17 |
|
15,829,384 |
|
|
||||||||||||
|
Cash at bank and in hand
|
|
|
29,646,547 |
|
|
||||||||||||
|
|
|
|
63,254,541 |
|
|
||||||||||||
|
Creditors: amounts falling due within one year
|
18 |
|
10,189,403 |
|
|
||||||||||||
|
Net current assets
|
|
|
|
|
53,065,138 | ||||||||||||
|
Total assets less current liabilities
|
|
|
|
|
106,774,833 | ||||||||||||
|
Provision for liabilities and charges
|
19 |
|
|
|
4,107,442 | ||||||||||||
|
Net assets
|
|
|
|
|
102,667,391 | ||||||||||||
|
Capital and reserves
|
|
|
|
|
|
||||||||||||
|
Called up share capital
|
21 |
|
|
|
948
|
||||||||||||
|
Capital redemption reserve
|
|
|
|
|
52
|
||||||||||||
|
Profit and loss account
|
22 |
|
|
|
102,666,391 | ||||||||||||
|
Shareholders' funds
|
23 |
|
|
|
102,667,391 | ||||||||||||
|
|
Note
|
|
£
|
|||||||||||
|
Cash flows from operating activities
|
|
|
|
|||||||||||
|
Profit for the financial year
|
|
|
1,676,682 | |||||||||||
|
Adjustments for:
|
|
|
|
|||||||||||
|
Depreciation of tangible assets
|
|
|
3,128,147 | |||||||||||
|
Profit on sales of fixed assets
|
|
|
(2,123,156) | |||||||||||
|
Amortisation and impairment of intangibles
|
|
|
431,683 | |||||||||||
|
Investment impairment provision
|
|
|
19,992 | |||||||||||
|
Interest paid
|
|
|
40,858 | |||||||||||
|
Interest received
|
|
|
(683,695) | |||||||||||
|
Decrease in stocks
|
|
|
1,919,685 | |||||||||||
|
Increase in debtors
|
|
|
(1,749,737) | |||||||||||
|
Increase in creditors
|
|
|
1,027,575 | |||||||||||
|
Income taxes recovered
|
|
|
2,354,544 | |||||||||||
|
Cash generated from operating activities
|
|
|
6,042,578 | |||||||||||
|
|
|
|
|
|||||||||||
|
Cash flows from investing activities
|
|
|
|
|||||||||||
|
Proceeds from sale of tangible assets
|
|
|
3,500,000 | |||||||||||
|
Purchase of tangible assets
|
|
|
(1,545,901) | |||||||||||
|
Interest received
|
|
|
670,164 | |||||||||||
|
|
|
|
|
|||||||||||
|
Net cash generated from investing activities
|
|
|
2,624,263 | |||||||||||
|
|
|
|
|
|||||||||||
|
Cash flows from financing activities
|
|
|
|
|||||||||||
|
Interest paid
|
|
|
(41,700) | |||||||||||
|
Equity dividends paid
|
|
|
(450,000) | |||||||||||
|
|
|
|
|
|||||||||||
|
Net cash used in financing activities
|
|
|
(491,700) | |||||||||||
|
|
|
|
|
|||||||||||
|
Net increase in cash and cash equivalents
|
|
|
8,175,141 | |||||||||||
|
Cash and cash equivalents at beginning of year
|
|
21,471,406 | ||||||||||||
|
|
|
|
|
|||||||||||
|
Cash and cash equivalents at end of year
|
24 |
|
29,646,547 | |||||||||||
|
Investment properties
|
-
|
Carried at fair value
|
||||||
|
Freehold land
|
-
|
Not depreciated
|
||||||
|
Freehold buildings
|
-
|
2% or 2.5% on cost, depending upon worldwide location and environment, from date asset brought into use
|
||||||
|
Short leasehold property
|
-
|
Depreciated over the term of the lease
|
||||||
|
Motor vehicles
|
-
|
25% per annum, reducing balance
|
||||||
|
Plant, machinery and equipment
|
-
|
15% per annum, reducing balance
|
||||||
|
Office equipment
|
-
|
15% per annum, reducing balance
|
||||||
|
Computer equipment
|
-
|
33 1/3% per annum, reducing balance
|
||||||
|
|
|
|
||||||
|
Analysed by geographical area
|
|
2025
|
||||||
|
|
|
£
|
||||||
|
United Kingdom
|
|
4,883,994 | ||||||
|
Canada and USA
|
|
24,000,928 | ||||||
|
Europe and Scandinavia
|
|
34,248,369 | ||||||
|
Australia and New Zealand
|
|
933,904 | ||||||
|
Africa
|
|
51,093 | ||||||
|
Far East
|
|
2,861,424 | ||||||
|
South Asia
|
|
1,546,942 | ||||||
|
Middle East
|
|
39,291 | ||||||
|
|
|
68,565,945 | ||||||
|
Analysed by category
|
|
2025
|
||||||
|
|
|
£
|
||||||
|
Medical Devices - Product sales
|
|
42,486,151 | ||||||
|
Pharmaceutical Services - Product sales
|
|
24,663,118 | ||||||
|
Development, services and equipment sales
|
|
1,416,676 | ||||||
|
|
|
|
||||||
|
|
|
68,565,945 | ||||||
|
2025
|
||||||||||||||
|
£
|
||||||||||||||
|
Depreciation on tangible assets:
|
|
3,128,147 | ||||||||||||
| Impairment charge on intangible assets | 383,718 | |||||||||||||
|
Payments under operating leases:
|
|
|
||||||||||||
|
For vehicle contract hire
|
|
191,413 | ||||||||||||
|
For hire of plant, machinery and office equipment
|
|
173,083 | ||||||||||||
|
Premises rent paid:
|
third parties
|
|
124,571 | |||||||||||
|
Foreign exchange (gains)
|
|
(299,124) | ||||||||||||
|
And after crediting the following:
|
|
|||||||||||||
|
Rents receivable (external)
|
|
216,351 | ||||||||||||
|
Royalties and similar income
|
|
1,887,065 | ||||||||||||
|
Grant income
|
|
8,024 | ||||||||||||
|
2025
|
|||||||||||
|
£
|
|||||||||||
|
Remuneration and other emoluments
|
|
466,866 | |||||||||
|
Pension contributions - money purchase schemes
|
|
40,000 | |||||||||
|
|
|
506,866 | |||||||||
|
Amounts included above for:
|
|
||||||||||
|
Highest paid director:
|
Remuneration and other emoluments
|
|
243,433 | ||||||||
|
|
Pension contributions
|
|
10,000 | ||||||||
|
2025
|
|||||
|
£
|
|||||
|
Profit on sale of fixed assets
|
2,123,156 | ||||
|
2025
|
||||||||
|
£
|
||||||||
|
Bank and other interest receivable
|
|
670,164 | ||||||
|
2025
|
||||||||
|
£
|
||||||||
|
Bank charges and interest on overdrafts wholly repayable within five years
|
|
41,700 | ||||||
|
2025
|
||||||||
|
£
|
||||||||
|
Corporation tax at an effective 25% on results, as adjusted
|
|
(497,087) | ||||||
|
Corporation tax provided in previous years
|
|
23,316 | ||||||
|
Transfer from deferred taxation account
|
|
394,541 | ||||||
|
Overseas taxation in subsidiaries
|
|
329,040 | ||||||
|
|
|
249,810 | ||||||
|
|
||||||||
|
Deferred tax of £413,825 is expected to reverse in the next year as accelerated capital allowances reduce. The Company has used brought forward tax losses which had reduced tax payments in recent years.
Factors affecting the tax charge
The tax assessed for the year is lower than the standard rate of corporation tax in the UK. The difference is explained below:
|
||||||||
|
|
|
2025
|
||||||
|
|
|
£
|
||||||
|
Result on ordinary activities multiplied by the standard rate of corporation tax in the UK of an effective 25%
|
|
668,803 | ||||||
|
Effect of:
Research and development tax credit and patent box
|
|
(400,000) | ||||||
|
Different rates of tax on overseas earnings
|
|
1,136 | ||||||
|
Capital allowances in excess of depreciation
|
|
143,906 | ||||||
|
Tax over provided in prior years
|
|
23,316 | ||||||
|
Tax losses set against taxable profits
|
|
(300,786) | ||||||
|
Difference in taxable profit on sales of property (indexation)
|
|
(375,543) | ||||||
|
Other reconciling differences (including dividend receipts)
|
|
94,437 | ||||||
|
Deferred tax adjustment
|
|
394,541 | ||||||
|
|
|
249,810 | ||||||
|
2025
|
||||||||
|
£
|
||||||||
|
Equity dividends paid
|
|
450,000 | ||||||
|
|
|
|
||||||
|
Intangible Assets
|
|
Total
|
|||||||||
|
|
£
|
|
£
|
||||||||
|
Cost or Valuation
|
|
|
|
||||||||
|
As at 1st October 2024
|
479,648 | 479,648 | |||||||||
|
Additions in year
|
- |
|
- | ||||||||
|
Disposals in year
|
- |
|
- | ||||||||
|
As at 30th September 2025
|
479,648 |
|
479,648 | ||||||||
|
Accumulated amortisation
|
|
|
|
||||||||
|
As at 1st October 2024
|
47,965 |
|
47,965 | ||||||||
|
Amortisation charge
|
47,965 | 47,965 | |||||||||
|
Impairment charge
|
383,718 | 383,718 | |||||||||
|
As at 30th September 2025
|
479,648 |
|
479,648 | ||||||||
|
Net book value
As at 30th September 2025
|
- |
|
- | ||||||||
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||
|
|
Freehold
|
|
Plant,
|
|
|
|
|
||||||||||||||||||||||
|
Investment property
|
|
Other land and buildings
|
|
machinery and equipment
|
|
Motor Vehicles
|
|
Total
|
|||||||||||||||||||||
|
|
£
|
|
£
|
|
£
|
|
£
|
|
£
|
||||||||||||||||||||
|
Cost or Valuation
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||
|
As at 1st October 2024
|
2,420,000 |
|
48,387,823 |
|
52,536,680 |
|
13,849 |
|
103,358,352 | ||||||||||||||||||||
|
Additions in year
|
- |
|
64,837 |
|
1,481,064 |
|
- |
|
1,545,901 | ||||||||||||||||||||
|
Disposals in year
|
- |
|
(5,618,937) |
|
(777,105) |
|
- |
|
(6,396,042) | ||||||||||||||||||||
|
Exchange adjustment
|
- |
|
(153,613) |
|
(123,880) |
|
- |
|
(277,493) | ||||||||||||||||||||
|
As at 30th September 2025
|
2,420,000 |
|
42,680,110 |
|
53,116,759 |
|
13,849 |
|
98,230,718 | ||||||||||||||||||||
|
Accumulated Depreciation
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||
|
As at 1st October 2024
|
- |
|
9,712,598 |
|
34,459,785 |
|
13,465 |
|
44,185,848 | ||||||||||||||||||||
|
Charge for year
|
- |
|
809,720 |
|
2,318,331 |
|
96
|
|
3,128,147 | ||||||||||||||||||||
|
Released on disposals
|
- |
|
(2,202,576) |
|
(526,463) |
|
- |
|
(2,729,039) | ||||||||||||||||||||
|
Exchange adjustment
|
- |
|
(15,647) |
|
(48,286) |
|
- |
|
(63,933) | ||||||||||||||||||||
|
As at 30th September 2025
|
- |
|
8,304,095 |
|
36,203,367 |
|
13,561 |
|
44,521,023 | ||||||||||||||||||||
|
Net book value
As at 30th September 2025
|
2,420,000 |
|
34,376,015 |
|
16,913,392 |
|
288
|
|
53,709,695 | ||||||||||||||||||||
|
2025
|
||||||||
|
£
|
||||||||
|
Unlisted Investments
|
|
|
||||||
|
Cost
|
|
|
||||||
|
Opening cost brought forward
|
|
815,820 | ||||||
|
Additions
|
|
- | ||||||
|
As at 30th September
|
|
815,820 | ||||||
|
Provision for Impairment
|
|
|
||||||
|
Opening provision brought forward
|
|
795,828 | ||||||
|
Movement in the year
|
|
19,992 | ||||||
|
As at 30th September
|
|
815,820 | ||||||
|
Carrying Value
|
|
|
||||||
|
As at 30th September
|
|
- | ||||||
|
2025
|
||||||||
|
£
|
||||||||
|
|
|
|||||||
|
Finished goods and goods for resale
|
|
8,646,374 | ||||||
|
Work in progress
|
|
2,152,862 | ||||||
|
Raw materials
|
|
6,979,374 | ||||||
|
|
|
17,778,610 | ||||||
|
2025
|
||||||||
|
£
|
||||||||
|
Trade debtors
|
|
10,641,481 | ||||||
|
Bad debt provisions
|
|
(92,667) | ||||||
|
Prepayments
|
|
1,391,202 | ||||||
|
Corporation and overseas profits tax recoverable
|
|
1,181,120 | ||||||
|
Other debtors
|
|
2,708,248 | ||||||
|
|
|
15,829,384 | ||||||
|
2025
|
||||||||
|
£
|
||||||||
|
Trade creditors
|
|
8,890,335 | ||||||
|
Unpaid directors' remuneration
|
|
57,000 | ||||||
|
Directors' and shareholders' loan accounts
|
|
6,419 | ||||||
|
Payroll and other taxes
|
|
941,087 | ||||||
|
Accruals and sundry creditors
|
|
294,562 | ||||||
|
|
|
10,189,403 | ||||||
|
2025
|
||||||||
|
£
|
||||||||
|
Provisions brought forward
|
|
3,712,901 | ||||||
|
Transfer from taxation account
|
|
394,541 | ||||||
|
Provision carried forward
|
|
4,107,442 | ||||||
|
The deferred tax account consists of the tax effect of timing differences in respect of:
|
||||||||
|
|
|
2025
|
||||||
|
|
|
£
|
||||||
|
Accelerated capital allowances
|
|
4,264,907 | ||||||
|
Tax losses
|
|
(612,889) | ||||||
|
Property revaluations
|
|
455,424 | ||||||
|
|
|
4,107,442 | ||||||
|
2025
|
||||||||
|
£
|
||||||||
|
Trade debtors
|
|
10,641,481 | ||||||
|
Other debtors
|
|
2,708,248 | ||||||
|
Total financial assets measured at amortised cost
|
|
13,349,729 | ||||||
|
Trade creditors
|
|
8,890,335 | ||||||
|
Accruals
|
|
300,981 | ||||||
|
Total financial liabilities measured at amortised cost
|
|
9,191,316 | ||||||
|
2025
|
||||||||
|
£
|
||||||||
|
Authorised
|
|
|
||||||
|
1,000,000 ordinary A shares of 50 pence each
|
|
500,000 | ||||||
|
5,000,000 ordinary B shares of 10 pence each
|
|
500,000 | ||||||
|
|
|
1,000,000 | ||||||
|
|
|
|
||||||
|
Issued and fully paid
|
|
£
|
||||||
|
948 ordinary A shares of 50 pence each
|
|
474
|
||||||
|
4,740 ordinary B shares of 10 pence each
|
|
474
|
||||||
|
|
|
948
|
||||||
|
|
|
|
||||||
|
The Company's share capital was restructured on 27th October 2005 upon approval by the Directors, being subdivided and converted into 948 ordinary 'A' shares of 50 pence each, and 4,740 ordinary 'B' shares of 10 pence each. The different shares carry different rights, but the issued share capital value remains unchanged.
|
||||||||
|
2025
|
||||||||
|
£
|
||||||||
|
Balance at 1st October 2024
|
|
101,800,502 | ||||||
|
Profit retained for the year after dividends
|
|
865,889 | ||||||
|
Balance at 30th September 2025
|
|
102,666,391 | ||||||
|
2025
|
||||||||
|
£
|
||||||||
|
Profit for the year after taxation
|
|
1,315,889 | ||||||
|
Dividends paid
|
|
(450,000) | ||||||
|
Net addition to shareholders' funds
|
|
865,889 | ||||||
|
Shareholders' funds at 1st October 2024
|
|
101,801,502 | ||||||
|
Shareholders' funds at 30th September 2025
|
|
102,667,391 | ||||||
|
2025
|
||||||||
|
£
|
||||||||
|
Cash
|
|
29,646,547 | ||||||
|
|
|
29,646,547 | ||||||
|
Subsidiaries
|
Country of registration
|
Shareholding ordinary shares / common stock)
|
|
Status
|
||||||||||
|
Owen Mumford Limited
|
England
|
100%
|
|
Trading
|
||||||||||
|
Medicross Limited
|
England
|
100% |
|
Dormant
|
||||||||||
|
Owen Mumford GmbH
|
Germany
|
100% |
|
Trading
|
||||||||||
|
Owen Mumford USA, Inc.
|
USA
|
100% |
|
Trading
|
||||||||||
|
OM-Medical-Shop GmbH
|
Germany
|
100% |
|
Dormant
|
||||||||||
|
Owen Mumford Sdn. Bhd.
|
Malaysia
|
100% |
|
Trading
|
||||||||||
|
Owen Mumford Technology Limited
|
England
|
100% |
|
Dormant
|
||||||||||
|
Payments due
|
2025
£
|
||||
|
Not later than one year
|
941,788 | ||||
|
Later than one year and not later than five years
|
2,785,938 | ||||
|
Later than five years
|
1,131,667 | ||||
|
|
4,859,393 | ||||
|
|
|
Year Ended
|
||||||
|
|
|
30 September 2025
|
||||||
|
|
Note
|
£
|
||||||
|
Total comprehensive income for the period in accordance to Local GAAP
|
|
1,315,889 | ||||||
|
US GAAP adjustments
|
|
|
||||||
|
Accounting for leases under US GAAP
|
1 | (30,920) | ||||||
| Accounting for investment property revaluation under US GAAP | 2 | (15,500) | ||||||
|
Total comprehensive income for the year in accordance to US GAAP
|
|
1,269,469 | ||||||
|
|
|
|
||||||
|
|
|
Year Ended
|
||||||
|
|
|
30th September 2025
|
||||||
|
|
Note
|
£
|
||||||
|
Total assets less current liabilities in accordance to Local GAAP
|
|
102,667,391 | ||||||
|
US GAAP adjustments
|
|
|
||||||
|
Accounting for leases under US GAAP
|
1 |
|
||||||
|
Addition of right of use asset
|
|
3,360,168 | ||||||
|
Addition of short term lease liability
|
|
(392,617) | ||||||
|
Addition of long term lease liability
|
|
(2,851,759) | ||||||
| Removal of prepaid rent | (146,712) | |||||||
|
Total impact of Accounting for leases under US GAAP
|
|
(30,920) | ||||||
| Accounting for Investment property under US GAAP | 2 | |||||||
| Removal of investment property revaluation surplus and addition of accumulated depreciation catch-up, net of tax | (1,635,201) | |||||||
| Total impact of Accounting for Investment property under US GAAP | (1,635,201) | |||||||
|
Total assets less current liabilities in accordance to US GAAP
|
|
101,001,270 | ||||||
|
|
|
|
||||||
|
Total capital and reserves in accordance to Local GAAP
|
|
102,667,391 | ||||||
|
US GAAP adjustments
|
|
|
||||||
| Accounting for operating leases under US GAAP | (30,920) | |||||||
| Accounting for investment property under US GAAP | (1,635,201) | |||||||
|
Total equity in accordance to US GAAP
|
|
101,001,270 | ||||||
|
|
|
|
||||||
|
|
|
Year Ended
|
||||||
|
|
|
30th September 2025
|
||||||
|
|
Note
|
£
|
||||||
|
Supplemental disclosures of noncash activity
|
|
|
||||||
|
Initial measurement of operating right of use assets
|
1 | 3,424,673 | ||||||
|
Initial measurement of operating lease liabilities
|
1 | (3,357,276) | ||||||